case_images: PMC11090123_01
case_images: Patient in Case 1 before Secukinumab 300mg treatment.
case_images: CCID-17-1043-g0001.jpg
case_images: PMC11090123_01_CCID-17-1043-g0001.jpg
case_images: f0001
case_images: To alleviate the symptoms, an additional 10 mg of rivaroxaban was administered, resulting in partial relief from pain, although a few new ulcers emerged (Figure 1).
case_images: Patient in Case 1 after Secukinumab 300mg treatment at week 1: more ulcers were noticed in the picture.
case_images: CCID-17-1043-g0002.jpg
case_images: PMC11090123_01_CCID-17-1043-g0002.jpg
case_images: f0002
case_images: Consequently, the patient was transitioned to anti-TNF therapy after the cough had resolved (Figure 2).
case_images: PMC11090123_02
case_images: Patient in Case 2 before Ixekizumab 160mg treatment.
case_images: CCID-17-1043-g0003.jpg
case_images: PMC11090123_02_CCID-17-1043-g0003.jpg
case_images: f0003
case_images: A 38-year-old man previously diagnosed with ankylosing spondylitis (AS) presented with a six-year history of ulcerated erythema and atrophied scars (Figure 3).
case_images: Patient in Case 2 after Ixekizumab 160mg treatment at week 2: ulcers were almost same compared to the baseline.
case_images: CCID-17-1043-g0004.jpg
case_images: PMC11090123_02_CCID-17-1043-g0004.jpg
case_images: f0004
case_images: However, by week four, the lesions had worsened, and several new ulcers appeared following the second dose (Figures 4 and 5).
case_images: Patient in Case 2 after Ixekizumab treatment twice at week 4: ulcered area were enlarged, and a bulla was noticed.
case_images: CCID-17-1043-g0005.jpg
case_images: PMC11090123_02_CCID-17-1043-g0005.jpg
case_images: f0005
case_images: However, by week four, the lesions had worsened, and several new ulcers appeared following the second dose (Figures 4 and 5).